Form 4: Xenon Pharmaceuticals Director Gillian Cannon Reports Acquisition of Stock Options and Restricted Share Units

Xenon Pharmaceuticals Inc. Director Gillian Cannon has reported the acquisition of 17,012 share options and 2,645 restricted share units as part of her compensation, aligning her interests with shareholders.

Summary

• Gillian Cannon, a Director of Xenon Pharmaceuticals Inc. (XENE), acquired 17,012 share options and 2,645 restricted share units (RSUs) on June 5, 2025.
• The share options have an exercise price of $30.73 per share and expire on June 4, 2035.
• Both the share options and restricted share units vest 100% on the earlier of June 4, 2026, or the day before the issuer's 2026 annual meeting of shareholders.
• Each restricted share unit represents a contingent right to receive one Common Share.
• Following these transactions, Ms. Cannon beneficially owns 17,012 share options and 2,645 restricted share units directly.

Sentiment

Score: 7

Explanation: The document reports a routine and expected insider transaction related to director compensation. This is generally positive as it aligns the director's interests with shareholders, but it does not indicate any new operational or financial performance that would significantly alter the company's outlook.

Positives

• The acquisition of share options and restricted share units by a director aligns their financial interests with those of the company's shareholders, promoting long-term value creation.
• This transaction represents a standard form of equity compensation for directors, indicating ongoing commitment to the company.

Future Outlook

The vesting schedule for the acquired share options and restricted share units indicates that the director's full beneficial ownership of these securities will materialize by June 4, 2026, or prior to the 2026 annual meeting, reinforcing a long-term stake in the company's performance.

Industry Context

The granting of stock options and restricted share units to directors is a common practice in the biotechnology and pharmaceutical industry, serving as a key component of executive and director compensation packages designed to incentivize performance and align interests with shareholders.

Comparison to Industry Standards

• The compensation structure, involving both stock options and restricted share units with a vesting schedule, is consistent with typical director compensation practices observed across publicly traded biotechnology and pharmaceutical companies like Biogen Inc. or Vertex Pharmaceuticals Inc., which often use equity awards to attract and retain talent and align long-term interests.
• The exercise price of $30.73 for the options is a standard grant price, usually based on the stock's market price at the time of grant, similar to how companies like Amgen Inc. or Gilead Sciences Inc. structure their option grants.

Related Party Transactions

• The acquisition of share options and restricted share units by Gillian Cannon, a Director of Xenon Pharmaceuticals Inc., constitutes a related party transaction as it involves compensation from the company to an insider.

Stakeholder Impact

• Shareholders: The equity awards align the director's financial interests with those of the shareholders, potentially leading to better long-term decision-making aimed at increasing shareholder value.
• Employees: While not directly impacting all employees, the compensation structure for directors can set a precedent for broader equity compensation plans within the company.

Next Steps

• The share options and restricted share units are scheduled to vest 100% on the earlier of June 4, 2026, or the day before the issuer's 2026 annual meeting of shareholders.

Key Dates

Keywords

Xenon Pharmaceuticals, XENE, Form 4, Insider Transaction, Stock Options, Restricted Share Units, Director Compensation, Beneficial Ownership, Equity Compensation